Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of eplontersen in transthyretin-mediated amyloid cardiomyopathy
2019-002835-27Phase 3Active
- Sponsor
- Ionis Pharmaceuticals
- Start
- Nov 2019
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in amyloidotic transthyretin cardiomyopathy (ATTR-CM) comparing eplontersen plus standard of care with placebo plus standard of care (2 arms). Primary endpoint: Composite of cardiovascular death and recurrent cardiovascular clinical events. Started Nov 2019; status: active.
02
Drugs
eplontersen
03
Conditions
amyloidotic transthyretin cardiomyopathy (ATTR-CM)
Beyond the preview
Go deeper on 2019-002835-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002835-27.